1. Many U.S. adults with high LDL-C are not receiving recommended therapy.
2. Study analyzed data from nearly 5,000 adults (NHANES 2013-2020).
3. Full guideline adherence could reduce cardiovascular events by 21-27%.
4. Potential annual savings of $25-$32 billion in healthcare costs.
5. Low usage noted for non-statin therapies such as xyz.
6. 47-88% of adults were eligible for cholesterol treatment.
7. The 2019 EU guideline targets showed the greatest benefits.
8. The study signals the need for better implementation of cholesterol management strategies.

Source: Springer Nature Link